Daasity vs Kenvue
Side-by-side comparison of AI visibility scores, market position, and capabilities
San Diego ecommerce analytics platform founded 2017; raised $12M+; consolidates DTC and omnichannel data into a warehouse-first model powering Looker, Tableau, and Power BI dashboards.
About
Daasity was founded in 2017 in San Diego, California and raised over $12M to build a data analytics platform for DTC and omnichannel brands that want consolidated business intelligence without building internal data engineering infrastructure. The company takes a data warehouse-first approach, integrating e-commerce, advertising, subscription, wholesale, and retail data into a centralized data model that powers both Daasity's own analytics dashboards and feeds into business intelligence tools like Looker, Tableau, and Power BI.\n\nDaasity's pre-built data models and connectors are designed around the specific metrics that DTC operators care about: customer acquisition cost by channel, lifetime value by cohort and acquisition source, contribution margin by SKU and channel, subscription churn and retention, and wholesale versus DTC revenue mix. This DTC-specific data modeling dramatically reduces the time brands need to go from raw data to actionable analytics compared to building custom data models from scratch.\n\nDaasity serves omnichannel brands that sell through a combination of their own DTC website, Shopify, wholesale, Amazon, and retail, with the ability to model the economics of each channel consistently. The company competes against TripleWhale, Northbeam, and Polar Analytics in the DTC analytics space, differentiating through its omnichannel scope, data warehouse flexibility, and appeal to brands with analytics-literate teams that want more control over their data modeling than opinionated analytics dashboards allow.
Skillman NJ consumer health (NYSE: KVUE) ~$15.5B FY2024 revenue; J&J spinoff May 2023, Tylenol/Band-Aid/Neutrogena/Listerine/Aveeno portfolio, talc litigation exposure competing with Haleon and P&G.
About
Kenvue Inc. is a Skillman, New Jersey-based consumer health company — publicly traded on the New York Stock Exchange (NYSE: KVUE) as an S&P 500 Consumer Staples component — marketing and selling over-the-counter medicines, skin health and beauty products, and essential health products through iconic consumer brands including Tylenol (pain and fever relief), Band-Aid (wound care), Neutrogena (skin care), Johnson's (baby care), Listerine (oral care), Aveeno (skincare), Motrin/Advil (ibuprofen pain relief), Zyrtec (allergy), Nicorette (smoking cessation), Neosporin (antibiotic ointment), and Benadryl through approximately 22,000 employees in 165 countries. Kenvue was separated from Johnson & Johnson through an IPO in May 2023 (the largest US IPO of 2023) and a tax-free distribution of J&J's remaining 89.6% stake to J&J shareholders in August 2023 — creating the world's largest pure-play consumer health company by market capitalization, with J&J retaining no ownership. In fiscal year 2024, Kenvue reported revenues of approximately $15.5 billion, with organic growth facing headwinds from lower cold/cough/flu season severity (Tylenol, Zyrtec, Benadryl volume sensitive to respiratory illness intensity), competitive pressure in skin health (Neutrogena competing with Korean beauty brands, Cerave, and pharmacy private label), and macroeconomic consumer trading down to lower-price alternatives in some markets. CEO Thibaut Mongon leads Kenvue's strategy of investing in the brand superiority of its household name portfolio while improving operational efficiency in the post-spinoff period (implementing Kenvue's own supply chain infrastructure, IT systems, and organizational structure previously shared with J&J).
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.